Evidence map›Paper›PMID 34433331›Full record

SynthesisThe Journal of international medical research2021

Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis.

Yin Wang, Yanqing Li, Ye Chai

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yin WangDepartment of Haematology, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China.ORCID https://orcid.org/0000-0002-5269-6818
Yanqing LiDepartment of Haematology, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China.
Ye ChaiDepartment of Haematology, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China.
Lanzhou University Second Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo systematically evaluate the efficacy and safety of combination regimens containing daratumumab in patients with multiple myeloma (MM).

methodsA systematic search of publications listed on electronic databases (PubMed®, The Cochrane Library, Science Direct and Web of Science) between inception and 13 November 2020 was conducted to find randomized controlled trials (RCTs) that included patients with MM that were treated with combination regimens containing daratumumab.

resultsA total of seven RCTs were included (

conclusionThe available evidence demonstrated that the clinical application of combination regimens containing daratumumab improved the efficacy in patients with MM and had acceptable safety.

Indexed as

Multiple MyelomaNeutropeniaAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansAntibodies, MonoclonaldaratumumabCD38Daratumumabmeta-analysismultiple myelomasystematic review

Identifiers

PMID34433331
PMCPMC8404651
OpenAlexW3163971228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.